This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
CD134 (OX40) Monoclonal Antibody (OX-86), APC, eBioscience
catalog :
17-1341-82
quantity :
100 ug
price :
US 362.00
clonality :
monoclonal
host :
rat
conjugate :
APC
clone name :
OX-86

The same clone is also sold as:
reactivity :
mouse
application :
flow cytometry
citations: 32
Reference
Harb H, Benamar M, Lai P, Contini P, Griffith J, Crestani E, et al. Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections. Immunity. 2021;54:1186-1199.e7 pubmed publisher
Stokes J, Hoffman E, Molina M, Kummet N, Simpson R, Zeng Y, et al. Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia. Oncoimmunology. 2020;9:1758011 pubmed publisher
Zhang C, Jin H, Wang Y, Li C, Zhao X, Li Y, et al. Critical role of OX40 in drug-induced acute liver injury. Br J Pharmacol. 2020;177:3183-3196 pubmed publisher
Choi H, Deng J, Li S, Silk T, Dong L, Brea E, et al. Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell Rep. 2019;27:806-819.e5 pubmed publisher
Araujo Furlan C, Tosello Boari J, Rodríguez C, Canale F, Fiocca Vernengo F, Boccardo S, et al. Limited Foxp3+ Regulatory T Cells Response During Acute Trypanosoma cruzi Infection Is Required to Allow the Emergence of Robust Parasite-Specific CD8+ T Cell Immunity. Front Immunol. 2018;9:2555 pubmed publisher
Publicover J, Gaggar A, Jespersen J, Halac U, JOHNSON A, Goodsell A, et al. An OX40/OX40L interaction directs successful immunity to hepatitis B virus. Sci Transl Med. 2018;10: pubmed publisher
Sitrin J, Suto E, Wuster A, Eastham Anderson J, Kim J, Austin C, et al. The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice. J Immunol. 2017;199:1238-1249 pubmed publisher
Zhang Z, Liu Q, Leskov K, Wu X, Duan J, Zhang G, et al. Roscovitine suppresses CD4+ T cells and T cell-mediated experimental uveitis. PLoS ONE. 2013;8:e81154 pubmed publisher
Yokota Nakatsuma A, Takeuchi H, Ohoka Y, Kato C, Song S, Hoshino T, et al. Retinoic acid prevents mesenteric lymph node dendritic cells from inducing IL-13-producing inflammatory Th2 cells. Mucosal Immunol. 2014;7:786-801 pubmed publisher
Majowicz A, van der Marel S, te Velde A, Meijer S, Petry H, van Deventer S, et al. Murine CD4?CD25? cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo. BMC Gastroenterol. 2012;12:172 pubmed publisher
Hagman D, Kuzma J, Larson I, Foster Schubert K, Kuan L, Cignarella A, et al. Characterizing and quantifying leukocyte populations in human adipose tissue: impact of enzymatic tissue processing. J Immunol Methods. 2012;386:50-9 pubmed publisher
Weiss R, Hessenberger M, Kitzmüller S, Bach D, Weinberger E, Krautgartner W, et al. Transcutaneous vaccination via laser microporation. J Control Release. 2012;162:391-9 pubmed publisher
Young J, Wu T, Chen Y, Zhao D, Liu H, Yi T, et al. Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. J Immunol. 2012;189:222-33 pubmed publisher
Chevrier S, Genton C, Malissen B, Malissen M, Acha Orbea H. Dominant Role of CD80-CD86 Over CD40 and ICOSL in the Massive Polyclonal B Cell Activation Mediated by LAT(Y136F) CD4(+) T Cells. Front Immunol. 2012;3:27 pubmed publisher
Rubinstein M, Cloud C, Garrett T, Moore C, Schwartz K, Johnson C, et al. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. 2012;214:700-7; discussion 707-8 pubmed publisher
Wythe S, Dodd J, Openshaw P, Schwarze J. OX40 ligand and programmed cell death 1 ligand 2 expression on inflammatory dendritic cells regulates CD4 T cell cytokine production in the lung during viral disease. J Immunol. 2012;188:1647-55 pubmed publisher
Hamano R, Huang J, Yoshimura T, Oppenheim J, Chen X. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol. 2011;41:2010-20 pubmed publisher
Gültner S, Kuhlmann T, Hesse A, Weber J, Riemer C, Baier M, et al. Reduced Treg frequency in LFA-1-deficient mice allows enhanced T effector differentiation and pathology in EAE. Eur J Immunol. 2010;40:3403-12 pubmed publisher
Damayanti T, Kikuchi T, Zaini J, Daito H, Kanehira M, Kohu K, et al. Serial OX40 engagement on CD4+ T cells and natural killer T cells causes allergic airway inflammation. Am J Respir Crit Care Med. 2010;181:688-98 pubmed publisher
Chen M, Yan B, Bando Y, Kuchroo V, Weiner H. Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol. 2008;180:7327-37 pubmed
Wang Y, Li M, Song M, Xu X, Xiong J, Yang X, et al. Expression of OX40 ligand in microglia activated by IFN-gamma sustains a protective CD4+ T-cell response in vitro. Cell Immunol. 2008;251:86-92 pubmed publisher
Xiu Y, Wong C, Bouaziz J, Hamaguchi Y, Wang Y, Pop S, et al. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol. 2008;180:2863-75 pubmed
Marshall N, Oda S, London C, Moulton H, Iversen P, Kerkvliet N, et al. Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. J Immunol Methods. 2007;325:114-26 pubmed
Bossaller L, Burger J, Draeger R, Grimbacher B, Knoth R, Plebani A, et al. ICOS deficiency is associated with a severe reduction of CXCR5+CD4 germinal center Th cells. J Immunol. 2006;177:4927-32 pubmed
Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick J, Tsai M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol. 2006;176:2238-48 pubmed
Andarini S, Kikuchi T, Nukiwa M, Pradono P, Suzuki T, Ohkouchi S, et al. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res. 2004;64:3281-7 pubmed
Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A. 2003;100:5986-90 pubmed
Kjaergaard J, Peng L, Cohen P, Drazba J, Weinberg A, Shu S. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol. 2001;167:6669-77 pubmed
Bansal Pakala P, Jember A, Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med. 2001;7:907-12 pubmed
Gramaglia I, Jember A, Pippig S, Weinberg A, Killeen N, Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol. 2000;165:3043-50 pubmed
Higgins L, McDonald S, Whittle N, Crockett N, Shields J, MacDonald T. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol. 1999;162:486-93 pubmed
Al Shamkhani A, Birkeland M, Puklavec M, Brown M, James W, Barclay A. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur J Immunol. 1996;26:1695-9 pubmed
product information
Product Type :
Antibody
Product Name :
CD134 (OX40) Monoclonal Antibody (OX-86), APC, eBioscience
Catalog # :
17-1341-82
Quantity :
100 ug
Price :
US 362.00
Clonality :
Monoclonal
Purity :
Affinity chromatography
Host :
Rat
Reactivity :
Mouse
Applications :
Flow Cytometry: 0.25 ug/test
Species :
Mouse
Clone :
OX-86
Isotype :
IgG1, kappa
Storage :
4 C, store in dark, DO NOT FREEZE!
Description :
OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 0.25 ug/test
Aliases :
ACT35; ACT35 antigen; ATC35 antigen; CD134; CD134 antigen; IMD16; Ly-70; lymphoid activation antigene ACT35; MRC OX40; Ox40; OX40 antigen; OX40 cell surface antigen; OX40 homologue; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor; tax-transcriptionally activated glycoprotein 1; tax-transcriptionally activated glycoprotein 1 receptor; TNF receptor superfamily member 4; Tnfrsf4; tumor necrosis factor (ligand) superfamily member 4; tumor necrosis factor receptor superfamily member 4; tumor necrosis factor receptor superfamily, member 4; tumor necrosis factor superfamily, member 4; Txgp1; Txgp1l
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA